Pharma BD Deal Intelligence

EyeTech Pharmaceuticals Inc. / Gilead Sciences Inc. (NX-1838 license)

2000 · Licensing/Option · $32M · Complete

Gilead exclusively licensed NX-1838 (anti-VEGF aptamer) to EyeTech for AMD: $7M upfront and up to $25M development milestones to Gilead. NX-1838 became pegaptanib (Macugen), approved by FDA in 2004 — first anti-VEGF for wet AMD. Strategically notable below $250M threshold; included for historical importance.

Did it work? Outcome assessment

Assessment window: 10yr post-close.

Key facts

• Announced Mar 30, 2000
• Closed Mar 30, 2000
• Deal value $32M
• Deal type Licensing/Option
• Therapeutic area Neovascular age-related macular degeneration (wet AMD)
• Indications Neovascular age-related macular degeneration (wet AMD)
• Key assets NX-1838 (later pegaptanib / Macugen)
• Mechanism Anti-VEGF aptamer

← Browse all deals  ·  How we score deals